Novartis AG (NVS)
Makes medicines to treat cancer, heart disease, autoimmune conditions, and rare genetic disorders.
$159.71+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+38.5%
The outlook
Novartis is trading near the upper end of its 52-week range, well above both its 50- and 200-day moving averages, suggesting near-term momentum. Analyst consensus leans toward a "Hold," with the average price target sitting about 3% below the current level. The stock carries a trailing P/E of 24.1, reflecting a valuation premium in the healthcare sector.
What’s behind the score
Analyst consensusHold — 2.8 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range82% of the way from its 52-week low to high
Price targetAvg target -3% vs current price
Analyst price target
~12-month · 10 analysts$155.37average target-2.7% vs now
Now $159.71
Low $123.00High $180.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$303.56B
52-wk high
$170.46
52-wk low
$112.34
50-day avg
$151.84
200-day avg
$145.71
Trailing P/E
24.1